ST Humanwell Drug Approved for Labor Analgesia Clinical Trial
ST Humanwell (600079) announced on August 10 that it has received approval to conduct a clinical trial for a drug intended for use as an analgesic combined with bupivacaine via epidural administration for labor pain relief. According to the notification, the drug is approved for the clinical trial for the specified indication.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 40% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.